Towards personalized treatment for high risk endometrial cancer

Author(s):
Post, C.C.B.
Published
2023
Publication type
Doctoral Thesis

Abstract

This thesis focuses on treatment outcomes of high risk endometrial cancer and corresponding patients’ and clinicians’ preferences regarding adjuvant treatment decisions; molecular studies on the etiology of mismatch repair deficiency (MMRd) in intermediate and high risk endometrial cancer; and the combination of immunotherapy and PARP inhibition for the treatment of recurrent or metastatic endometrial cancer.

The overall aims of this thesis were:

• To evaluate health-related quality of life up to 5 years after chemoradiotherapy compared with pelvic radiotherapy alone in the adjuvant treatment of high risk endometrial cancer in the PORTEC-3 trial;

• To investigate the preferences of patients and clinicians regarding the benefit-risk trade-off of the addition of chemotherapy to adjuvant pelvic radiotherapy; • To investigate the prevalence and prognosis of Lynch syndrome-associated endometrial cancer among MMRd endometrial cancers; • To evaluate the role of combined checkpoint inhibition and PARP inhibition in women with metastatic or recurrent endometrial cancer in terms of progression-free survival and toxicity in the DOMEC trial.

Endometrial CancerRadiotherapyChemotherapyImmunotherapyPARP inhibitionQuality of LifeSensory NeuropathyMismatch Repair DeficiencyLynch Syndrome
Defense date
2023-06-13
Language
English
Supervisor(s)
Creutzberg, C.L.
Advisor(s)
Kroep, J.R.; Bosse, T.
Committee member(s)
Smit, V.H.B.T.M.; Gelderblom, A.J.; Westermann, A.M.; Poll-Franse, L.V. van de; Asperen, C.J. van
Qualification
Ph.D.
Degree granting institution
Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University, Leiden
hdl
1887/3620169
ISBN(s)
9789464693225